BiotechTube

Ramosetron + Placebo

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Irritable Bowel Syndrome

Conditions

Irritable Bowel Syndrome

Trial Timeline

Oct 1, 2010 → Aug 1, 2011

NCT ID
NCT01225237

About Ramosetron + Placebo

Ramosetron + Placebo is a approved stage product being developed by Astellas Pharma for Irritable Bowel Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01225237. Target conditions include Irritable Bowel Syndrome.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (2)

NCT IDPhaseStatus
NCT01225237ApprovedCompleted
NCT00918411ApprovedCompleted

Competing Products

20 competing products in Irritable Bowel Syndrome

See all competitors
ProductCompanyStageHype Score
linaclotide + placeboAstellas PharmaPhase 2
52
YM060 + PlaceboAstellas PharmaPhase 3
77
Ramosetron + PlaceboAstellas PharmaApproved
85
YM060Astellas PharmaPhase 3
77
YM060 + placeboAstellas PharmaPhase 2
52
YM060Astellas PharmaPhase 3
77
linaclotide + PlaceboAstellas PharmaPhase 3
77
RamosetronAstellas PharmaPre-clinical
23
YM060Astellas PharmaPhase 2
52
ONO-2952 + Placebo comparatorOno PharmaceuticalPhase 2
52
ONO-2952 + ONO-2952 Matching PlaceboOno PharmaceuticalPhase 2
52
duloxetineEli LillyApproved
85
Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers) + Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)AbbViePhase 3
77
25mg Eluxadoline + 100mg EluxadolineAbbViePhase 3
77
Eluxadoline + PlaceboAbbViePhase 2
52
Placebo + LinaclotideAstraZenecaPhase 3
77
TegaserodNovartisPre-clinical
23
DNK333NovartisPhase 2
52
SMS995 + PlaceboNovartisPhase 1
33
DNK333 + PlaceboNovartisPhase 2
52

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85